)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AlzChem Group
AlzChem Group (ACT) investor relations material
AlzChem Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
9M 2026 sales rose 4.5% to €443.8m; EBITDA increased 8.1% to €93.2m and margin expanded to 21.0%.
Specialty Chemicals led growth on strong nutrition and defense demand, offsetting weaker Basics & Intermediates results.
FY 2026 guidance was reaffirmed at ~€600m sales and ~€126m EBITDA, with ~21.0% EBITDA margin expected.
Financial highlights
Q3 sales increased 1.9% to €139.9m; EBITDA declined 3.5% to €28.7m and margin eased to 20.5% from 21.7%.
9M EBIT was €69.4m versus €66.5m; period result rose to €48.4m from €46.8m.
9M diluted EPS rose to €4.77 from €4.62; Q3 EPS fell to €1.34 from €1.61.
9M operating cash flow was €97.4m; investing outflow reached €117.6m, leaving free cash flow at -€20.2m.
Customer grants contributed €11.4m to 9M operating cash flow, versus €55.5m in 9M 2025.
Outlook and guidance
FY 2026 forecast reaffirmed: sales ~€600m (+7%), EBITDA ~€126m (+8%) and EBITDA margin ~21.0%.
Organic growth is expected to come from Specialty Chemicals; Basics & Intermediates sales are expected slightly below 2025.
First sales from expanded German guanidine nitrate and nitroguanidine capacity are expected in Q4 2026; creatine facility commissioning is scheduled from H2 2027.
Guidance assumes energy and raw-material cost increases are passed through or offset; further Iran-conflict and long-term supply-chain effects are excluded.
The ~€120m creatine capacity expansion remains on plan, with commissioning in phases from H2 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AlzChem Group
- Strong H1 2026 growth in sales and EBITDA, driven by Specialty Chemicals and new investments.ACT
H1 2026 - Q1 2026 saw 3% sales and 18% EBITDA growth, driven by Specialty Chemicals.ACTQ1 2026
- Specialty chemicals leader targets €600 million sales in 2026, driven by innovation and expansion.ACTCompany presentation
- Specialty chemicals growth and major investments drove record earnings and positive 2026 outlook.ACTH2 2025
- Specialty Chemicals drove robust sales, margin, and profit growth; 2025 outlook reaffirmed.ACTQ3 2025
- Specialty Chemicals drove H1 2025 growth and margins, supporting a strong outlook despite headwinds.ACTQ2 2025
- EBITDA up 36% and net income up 66% as Specialty Chemicals drive robust, grant-backed growth.ACTQ3 2024
- EBITDA up 10% and margin at 18.9% as Specialty Chemicals drive growth and 2025 outlook is confirmed.ACTQ1 2025
- Record 2024 results and strong 2025 outlook driven by Specialty Chemicals growth.ACTQ4 2024
Next AlzChem Group earnings date
Q4 202625 Feb, 2027
AlzChem Group
Next AlzChem Group earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AlzChem Group AG is a globally active specialty chemicals company, recognized as a market leader in many of its fields of activity. The company's diverse product range caters to various sectors, including human and animal nutrition, agriculture, pharmaceuticals, fine chemicals, metallurgy, and renewable energies. AlzChem's products are designed to address global trends and challenges such as climate change, population growth, and increasing life expectancy, providing solutions that contribute to sustainable development and efficient food production. The company prides itself on innovation and sustainability, with efforts aimed at achieving climate neutrality and improving corporate social responsibility outcomes. The company is headquartered in in Trostberg, Germany, and its shares are listed on the Frankfurt Stock Exchange.